Noteworthy Form D Filing: Neurotrope $24.51 million Fundraising. Robert Weinstein Released Nov 30 D form

Biotechnology Neurotrope, Inc. - Robert Weinstein

Neurotrope Financing

Neurotrope, Inc., Corporation just had published form D because of $24.51 million equity financing. This is a new filing. Neurotrope was able to sell $24.51 million. That is 100.00% of the financing offer. The total private offering amount was $24.51 million. The financing form was filed on 2016-11-30. The reason for the financing was: The two placement agents also received warrants to purchase stock..

Neurotrope is based in New York. The company’s business is Biotechnology. The form was signed by Robert Weinstein CFO, Executive VP, Secretary and Treasurer. The company was incorporated in 2013. The filler’s address is: 205 East 42Nd Street,, 16Th Floor, New York, Ny, New York, 10017. Robert Weinstein is the related person in the form and it has address: C/O Neurotrope, Inc., 205 East 42Nd Street, 16Th Floor, New York, Ny, New York, 10017. Link to Neurotrope Filing: 000151385616000003.

Analysis of Neurotrope Offering

On average, companies in the Biotechnology sector, sell 73.77% of the total offering size. Neurotrope sold 100.00% of the offering. Could this mean that the trust in Neurotrope is high? The average fundraising size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 695.65% bigger than the average for companies in the Biotechnology sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Neurotrope Also

The Form D signed by Robert Weinstein might help Neurotrope, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment